ED treatment is evolving faster than it has in years. New research, telehealth expansion, compounded medication growth, and pipeline drugs are reshaping options for men. This page tracks every significant development so you have one place to check for what's new.
Q1 2026 (January – March)
A comprehensive network meta-analysis published in Sexual Medicine Reviews (Vol. 14, Issue 1) compared five major non-pharmaceutical interventions for ED: electrical stimulation, pelvic floor muscle training, low-intensity shockwave therapy (Li-ESWT), acupuncture-based therapies, and hyperbaric oxygen therapy. The study searched eight databases covering literature through December 2025 and provides the most robust comparative evidence to date for men exploring alternatives to medication. Read our shockwave therapy analysis.
Researchers published insights from over 1,000 endovascular therapy procedures for ED — catheter-based treatments to open blocked penile and pelvic arteries. While still an emerging approach and not widely available, the growing dataset suggests a role for direct revascularization in select patients with documented arterial blockages. Read our full pipeline report.
A randomized double-blind, placebo-controlled trial testing adipose-derived regenerative cells injected into the corpora cavernosa in men with ED following radical prostatectomy reported results. This is the most rigorous stem cell study for ED to date. Results are being evaluated by the research community. Read our pipeline analysis.
Increasing competition among telehealth ED platforms has continued pushing generic medication prices lower. Several platforms now offer generic sildenafil for under $3/pill and daily tadalafil programs under $50/month without insurance. Budget platforms like MyDrHank offer prices as low as $1.67/pill. Read our no-insurance cost guide.
Dicot Pharma continued advancing LIB-01, a novel melanocortin receptor agonist that works through the central nervous system rather than penile vasculature. Researchers have highlighted both its erectile function potential and possible metabolic benefits. Still in early clinical development — commercial availability is years away. Read our LIB-01 analysis.
A randomized controlled trial comparing platelet-rich plasma (PRP) injections to placebo injections for mild-to-moderate ED found no significant difference between the two groups. While PRP was well-tolerated with no major side effects, the lack of meaningful improvement means PRP injections cannot currently be recommended as an evidence-based ED treatment. Men considering PRP should be aware that the available evidence does not support its efficacy.
What to Watch for in Q2–Q4 2026
- MED3000 topical gel — regulatory progress updates expected. Could become the first FDA-approved topical ED treatment.
- Additional GLP-1 + ED data — as more men use semaglutide and tirzepatide for weight loss, data on erectile function improvements in real-world populations will accumulate. Read our GLP-1 + ED guide.
- Generic compounded medication regulations — FDA oversight of compounding pharmacies producing ED combinations continues to evolve. May affect availability and pricing of compounded formulations.
- SMSNA position statements — the Sexual Medicine Society of North America published a 2026 position statement defining clinically relevant responses in erectile function, which may standardize how ED treatments are evaluated in trials going forward.
- AI integration in telehealth ED — several platforms are exploring AI-assisted initial screening and follow-up, potentially reducing costs and improving access further.
Don't Wait for Tomorrow's Treatments
Effective, affordable ED treatment is available today. Get started with a licensed provider.
Visit BraveRX Visit MyDrHank